P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

Opis bibliograficzny
Główni autorzy:	F. B. Askeland, E. Haukås, T. S. Slørdahl, D. Schjøll, A. Lysen, E. Hermansen, F. Schjesvold
Format:	Artykuł
Język:	English
Wydane:	Wiley 2022-06-01
Seria:	HemaSphere
Dostęp online:	http://journals.lww.com/10.1097/01.HS9.0000846428.64094.91

Podobne zapisy

P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
od: Frida Bugge Askeland, i wsp.
Wydane: (2023-08-01)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
od: Enrique M. Ocio, i wsp.
Wydane: (2023-02-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
od: Dong Liang, i wsp.
Wydane: (2024-09-01)

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
od: Wenjiao Tang, i wsp.
Wydane: (2024-01-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
od: Doris K. Hansen, i wsp.
Wydane: (2024-11-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
od: Juan José Gil‐Fernández, i wsp.
Wydane: (2024-01-01)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
od: Alessandra Larocca, i wsp.
Wydane: (2020-04-01)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
od: A. Oriol, i wsp.
Wydane: (2022-06-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
od: Zhongjun Huo, i wsp.
Wydane: (2023-02-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
od: Joshua Richter, i wsp.
Wydane: (2023-04-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
od: Carlyn Rose Tan, i wsp.
Wydane: (2023-07-01)

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)
od: M. D’Agostino, i wsp.
Wydane: (2022-06-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
od: N. O’Connor-Byrne, i wsp.
Wydane: (2019-02-01)

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
od: Efstathios Kastritis, i wsp.
Wydane: (2019-10-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
od: Yan Wang, i wsp.
Wydane: (2025-02-01)

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
od: E. K. Mai, i wsp.
Wydane: (2022-06-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
od: Yin-Che Wang, i wsp.
Wydane: (2025-12-01)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
od: Mattia D’agostino, i wsp.
Wydane: (2023-08-01)

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
od: A. Larocca, i wsp.
Wydane: (2023-05-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
od: Laura Rosiñol, i wsp.
Wydane: (2023-11-01)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
od: Joseph Kauer, i wsp.
Wydane: (2023-11-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
od: Junjing Yin, i wsp.
Wydane: (2024-11-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
od: Susana Aceituno, i wsp.
Wydane: (2018-06-01)

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis
od: Piechotta, V, i wsp.
Wydane: (2019)

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
od: Annemiek Broijl, i wsp.
Wydane: (2016-04-01)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
od: Paul G. Richardson, i wsp.
Wydane: (2023-08-01)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
od: Mohamad Mohty, i wsp.
Wydane: (2020-05-01)

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
od: Enrique M. Ocio, i wsp.
Wydane: (2010-05-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
od: Kristian T. Andersen, i wsp.
Wydane: (2020-01-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
od: C. Cerchione, i wsp.
Wydane: (2020-10-01)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
od: K. Weisel, i wsp.
Wydane: (2023-05-01)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
od: X. Jingyu, i wsp.
Wydane: (2022-06-01)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
od: Sebastian Grosicki, i wsp.
Wydane: (2023-08-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
od: Ajay K. Nooka, i wsp.
Wydane: (2022-04-01)

EVALUATION OF DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (D-VRD) INDUCTION FOLLOWED BY DARATUMUMAB AND LENALIDOMIDE (DR) MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN BRAZIL
od: JTD Souto-Filho, i wsp.
Wydane: (2024-10-01)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
od: Z. Zhuang, i wsp.
Wydane: (2022-06-01)

Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
od: Yuki Otani, i wsp.
Wydane: (2024-12-01)

Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
od: Paul G. Richardson, i wsp.
Wydane: (2024-02-01)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
od: Fredrik Schjesvold, i wsp.
Wydane: (2022-03-01)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
od: Fredrik H. Schjesvold, i wsp.
Wydane: (2020-06-01)